

Dawn F Ionescu

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/10468981/publications.pdf>

Version: 2024-02-01

42
papers

3,035
citations

201674

27
h-index

265206

42
g-index

43
all docs

43
docs citations

43
times ranked

2988
citing authors

#	ARTICLE	IF	CITATIONS
1	Esketamine Nasal Spray for Rapid Reduction of Depressive Symptoms in Patients With Major Depressive Disorder Who Have Active Suicide Ideation With Intent: Results of a Phase 3, Double-Blind, Randomized Study (ASPIRE II). <i>International Journal of Neuropsychopharmacology</i> , 2021, 24, 22-31.	2.1	280
2	The effect of esketamine in patients with treatment-resistant depression with and without comorbid anxiety symptoms or disorder. <i>Depression and Anxiety</i> , 2021, 38, 1120-1130.	4.1	11
3	Esketamine Nasal Spray for the Rapid Reduction of Depressive Symptoms in Major Depressive Disorder With Acute Suicidal Ideation or Behavior. <i>Journal of Clinical Psychopharmacology</i> , 2021, 41, 516-524.	1.4	32
4	The effect of single administration of intravenous ketamine augmentation on suicidal ideation in treatment-resistant unipolar depression: Results from a randomized double-blind study. <i>European Neuropsychopharmacology</i> , 2021, 49, 122-132.	0.7	17
5	Double-blind, placebo-controlled, dose-ranging trial of intravenous ketamine as adjunctive therapy in treatment-resistant depression (TRD). <i>Molecular Psychiatry</i> , 2020, 25, 1592-1603.	7.9	235
6	Time to relapse after a single administration of intravenous ketamine augmentation in unipolar treatment-resistant depression. <i>Journal of Affective Disorders</i> , 2020, 260, 131-139.	4.1	21
7	Studying pre-treatment and ketamine-induced changes in white matter microstructure in the context of ketamine's antidepressant effects. <i>Translational Psychiatry</i> , 2020, 10, 432.	4.8	20
8	Esketamine Nasal Spray for Rapid Reduction of Major Depressive Disorder Symptoms in Patients Who Have Active Suicidal Ideation With Intent. <i>Journal of Clinical Psychiatry</i> , 2020, 81, .	2.2	273
9	Efficacy of intravenous ketamine treatment in anxious versus nonanxious unipolar treatment-resistant depression. <i>Depression and Anxiety</i> , 2019, 36, 235-243.	4.1	37
10	Repeat-dose ketamine augmentation for treatment-resistant depression with chronic suicidal ideation: A randomized, double blind, placebo controlled trial. <i>Journal of Affective Disorders</i> , 2019, 243, 516-524.	4.1	120
11	Ketamine-Associated Brain Changes: A Review of the Neuroimaging Literature. <i>Harvard Review of Psychiatry</i> , 2018, 26, 320-339.	2.1	71
12	Becoming an Academic Researcher in Psychiatry: A View From the Trenches. <i>Academic Psychiatry</i> , 2017, 41, 293-296.	0.9	3
13	The Role of Chronic Stress in Anxious Depression. <i>Chronic Stress</i> , 2017, 1, 247054701668947.	3.4	26
14	Classics in Chemical Neuroscience: Ketamine. <i>ACS Chemical Neuroscience</i> , 2017, 8, 1122-1134.	3.5	87
15	The antidepressant efficacy of subanesthetic-dose ketamine does not correlate with baseline subcortical volumes in a replication sample with major depressive disorder. <i>Journal of Psychopharmacology</i> , 2017, 31, 1570-1577.	4.0	17
16	A placebo-controlled crossover study of iloperidone augmentation for residual anger and irritability in major depressive disorder. <i>Therapeutic Advances in Psychopharmacology</i> , 2016, 6, 4-12.	2.7	3
17	Ziprasidone augmentation for anxious depression. <i>International Clinical Psychopharmacology</i> , 2016, 31, 341-346.	1.7	8
18	Recognition of emotional facial expressions in anxious and nonanxious depression. <i>Comprehensive Psychiatry</i> , 2016, 70, 1-8.	3.1	16

#	ARTICLE	IF	CITATIONS
19	A randomized, placebo-controlled pilot trial of the delta opioid receptor agonist AZD2327 in anxious depression. <i>Psychopharmacology</i> , 2016, 233, 1119-1130.	3.1	59
20	Current Trends in Identifying Rapidly Acting Treatments for Depression. <i>Current Behavioral Neuroscience Reports</i> , 2016, 3, 185-191.	1.3	11
21	Rapid and Sustained Reductions in Current Suicidal Ideation Following Repeated Doses of Intravenous Ketamine. <i>Journal of Clinical Psychiatry</i> , 2016, 77, e719-e725.	2.2	100
22	Near-Infrared Transcranial Radiation for Major Depressive Disorder: Proof of Concept Study. <i>Psychiatry Journal</i> , 2015, 2015, 1-8.	1.5	90
23	Lithium and Valproate Levels Do Not Correlate with Ketamine's Antidepressant Efficacy in Treatment-Resistant Bipolar Depression. <i>Neural Plasticity</i> , 2015, 2015, 1-7.	2.2	17
24	Ketamine's Antidepressant Efficacy is Extended for at Least Four Weeks in Subjects with a Family History of an Alcohol Use Disorder. <i>International Journal of Neuropsychopharmacology</i> , 2015, 18, .	2.1	33
25	A single infusion of ketamine improves depression scores in patients with anxious bipolar depression. <i>Bipolar Disorders</i> , 2015, 17, 438-443.	1.9	88
26	Baseline working memory activation deficits in dimensional anxious depression as detected by magnetoencephalography. <i>Acta Neuropsychiatrica</i> , 2015, 27, 143-152.	2.1	28
27	Pharmacological approaches to the challenge of treatment-resistant depression. <i>Dialogues in Clinical Neuroscience</i> , 2015, 17, 111-126.	3.7	149
28	Increased fear-potentiated startle in major depressive disorder patients with lifetime history of suicide attempt. <i>Journal of Affective Disorders</i> , 2014, 162, 34-38.	4.1	30
29	Do the dissociative side effects of ketamine mediate its antidepressant effects?. <i>Journal of Affective Disorders</i> , 2014, 159, 56-61.	4.1	227
30	DEVELOPING BIOMARKERS IN MOOD DISORDERS RESEARCH THROUGH THE USE OF RAPID-ACTING ANTIDEPRESSANTS. <i>Depression and Anxiety</i> , 2014, 31, 297-307.	4.1	43
31	Glutamate and its receptors in the pathophysiology and treatment of major depressive disorder. <i>Journal of Neural Transmission</i> , 2014, 121, 907-924.	2.8	115
32	Riluzole likely lacks antidepressant efficacy in ketamine non-responders. <i>Journal of Psychiatric Research</i> , 2014, 58, 197-199.	3.1	20
33	Improvement in suicidal ideation after ketamine infusion: Relationship to reductions in depression and anxiety. <i>Journal of Psychiatric Research</i> , 2014, 58, 161-166.	3.1	224
34	Clinical Predictors of Ketamine Response in Treatment-Resistant Major Depression. <i>Journal of Clinical Psychiatry</i> , 2014, 75, e417-e423.	2.2	120
35	Effect of Baseline Anxious Depression on Initial and Sustained Antidepressant Response to Ketamine. <i>Journal of Clinical Psychiatry</i> , 2014, 75, e932-e938.	2.2	84
36	Pharmacologic Treatment of Dimensional Anxious Depression. primary care companion for CNS disorders, <i>The</i> , 2014, 16, .	0.6	32

#	ARTICLE	IF	CITATIONS
37	Experimental Pharmacologic Approaches for the Reduction of Suicidal Ideation and Behavior. , 2014, , 209-221.		0
38	Second messenger/signal transduction pathways in major mood disorders: moving from membrane to mechanism of action, part I: major depressive disorder. CNS Spectrums, 2013, 18, 231-241.	1.2	39
39	NEUROBIOLOGY OF ANXIOUS DEPRESSION: A REVIEW. Depression and Anxiety, 2013, 30, 374-385.	4.1	96
40	Subanesthetic Dose Ketamine Does Not Induce an Affective Switch in Three Independent Samples of Treatment-Resistant Major Depression. Biological Psychiatry, 2013, 74, e23-e24.	1.3	33
41	Defining anxious depression: a review of the literature. CNS Spectrums, 2013, 18, 252-260.	1.2	83
42	Major Depression Is Not Associated with Blunting of Aversive Responses; Evidence for Enhanced Anxious Anticipation. PLoS ONE, 2013, 8, e70969.	2.5	32